Statistik Asas
| LEI | 549300NCT4OJF7JV1084 |
| CIK | 1267813 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Marinus Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| February 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-36576 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specifi |
|
| February 14, 2025 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of Marinus Pharmaceuticals, Inc. and further agree to the filing of this agreement as an exhibi |
|
| February 12, 2025 |
EX-99 2 d11597485ex99-a.htm Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. 1 dated February 12, 2025 relating to the Common Stock, par value $0.001 per share, of Marinus Pharmaceuticals, Inc. shall be filed on behalf of the undersigned. SOFINNOVA INVESTMENTS, INC. By: /s/ James Healy Name: James Healy Title: Director SOFINNOVA BIOEQUITIES GP LLC By: /s/ |
|
| February 12, 2025 |
EX-99 3 dd11597485ex99-b.htm Exhibit B CONTROL PERSON IDENTIFICATION Sofinnova Investments, Inc. and Sofinnova BioEquities GP LLC are the relevant entities for which James Healy and Eric Delbridge, respectively, may be considered control persons. |
|
| February 11, 2025 |
EX-99 2 d11606221ex99-a.htm Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G Amendment No. 4 dated February 11, 2025 relating to the Common Stock, par value $0.001 per share, of Marinus Pharmaceuticals, Inc. shall be filed on behalf of the undersigned. SUVRETTA CAPITAL MANAGEMENT, LLC By: /s/ Aaron Cowen Name: Aaron Cowen Title: Authorized Signatory AVERILL MASTER FUND |
|
| February 11, 2025 |
FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION MARINUS PHARMACEUTICALS, INC. Exhibit 3.1 FIFTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF MARINUS PHARMACEUTICALS, INC. FIRST: The name of the corporation is Marinus Pharmaceuticals, Inc. (the “Corporation”). SECOND: The address of the Corporation’s registered office in the State of Delaware is The Corporation Trust Center, 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801. The name of its |
|
| February 11, 2025 |
EX-35 2 d11598865ex99-a.htm Exhibit A JOINT FILING AGREEMENT The undersigned agree that this Schedule 13G dated February 11, 2025 relating to the Common Stock, par value $0.001 per share, of Marinus Pharmaceuticals, Inc. shall be filed on behalf of the undersigned. SUVRETTA CAPITAL MANAGEMENT, LLC By: /s/ Aaron Cowen Name: Aaron Cowen Title: Authorized Signatory AVERILL MASTER FUND, LTD. By: /s/ A |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 11, 2025 |
EX-99 3 d11606221ex99-b.htm Exhibit B CONTROL PERSON IDENTIFICATION Suvretta Capital Management, LLC is the relevant entity for which Aaron Cowen is the control person. |
|
| February 11, 2025 |
EX-99 3 d11598865ex99-b.htm Exhibit B CONTROL PERSON IDENTIFICATION Suvretta Capital Management, LLC is the relevant entity for which Aaron Cowen is the control person. |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 11, 2025 |
Immedica completes acquisition of Marinus Pharmaceuticals, Inc. Exhibit 99.1 Press release Immedica completes acquisition of Marinus Pharmaceuticals, Inc. Stockholm, Sweden – February 11, 2025 – Immedica Pharma AB (“Immedica”), a leading global rare disease company, announced today the completion of the acquisition of Marinus Pharmaceuticals, Inc. (“Marinus”) (Nasdaq: MRNS) through its indirect wholly owned subsidiary Matador Subsidiary, Inc., a Delaware corpo |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2025 MARINUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Com |
|
| February 11, 2025 |
Exhibit 3.2 Final Version SECOND AMENDED AND RESTATED BYLAWS OF MARINUS PHARMACETUCIALS, INC., a Delaware corporation (the “Corporation”) Article I CORPORATE OFFICES Section 1.1 Registered Office. The registered office of the Corporation shall be fixed in the Certificate of Incorporation of the Corporation (as the same may be amended and/or restated from time to time, the “C |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2) Marinus Pharmaceuticals, Inc. (Name of Subject Company) Marinus Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class |
|
| February 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) MARINUS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) MATADOR SUBSIDIARY, INC. a direct wholly-owned subsidiary of IMMEDICA PHARMA AB (Name of Filing Persons (Offerors)) Common Stock, $0.001 |
|
| February 7, 2025 |
Exhibit (a)(5)(C) Press release Immedica successfully completes tender offer for all outstanding shares of common stock of Marinus Pharmaceuticals, Inc. |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) MARINUS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) MATADOR SUBSIDIARY, INC. a direct wholly-owned subsidiary of IMMEDICA PHARMA AB (Name of Filing Persons (Offerors)) Common Stock, $0.001 |
|
| January 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Amendment No. 1) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Marinus Pharmaceuticals, Inc. (Name of Subject Company) Marinus Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) |
|
| January 10, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Marinus Pharmaceuticals, Inc. (Name of Subject Company) Marinus Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class |
|
| January 8, 2025 |
Exhibit (a)(1)(B) Letter of Transmittal To Tender Shares of Common Stock of MARINUS PHARMACEUTICALS, INC. |
|
| January 8, 2025 |
Exhibit 107 Calculation of Filing Fee Table SCHEDULE TO-T (Rule 14d-100) Marinus Pharmaceuticals, Inc. |
|
| January 8, 2025 |
Exhibit (a)(1)(C) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Marinus Pharmaceuticals, Inc. |
|
| January 8, 2025 |
Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Marinus Pharmaceuticals, Inc. |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Tender Offer Statement under Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 MARINUS PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) MATADOR SUBSIDIARY, INC. a direct wholly-owned subsidiary of IMMEDICA PHARMA AB (Name of Filing Persons (Offerors)) Common Stock, $0.001 Par Value (Title |
|
| January 8, 2025 |
Exhibit 99.(a)(5)(B) Press release Immedica to commence tender offer for all outstanding shares of common stock of Marinus Pharmaceuticals, Inc. Stockholm, Sweden – January 8, 2025 – Immedica Pharma AB (“Immedica”), a leading global rare disease company, today announced that it will commence a tender offer through its wholly owned, direct subsidiary Matador Subsidiary, Inc., a Delaware corporation |
|
| January 8, 2025 |
Exhibit (d)(2) STRICTLY CONFIDENTIAL October 29, 2024 Immedica Pharma AB Solnavägen 3H, 113 63 Stockholm Attention: Anders Edvell, CEO Re: Non-Disclosure Agreement Ladies and Gentlemen: In connection with the consideration of a possible negotiated transaction (a “Possible Transaction”) involving Immedica Pharma AB, a Swedish corporation (collectively, with its subsidiaries, the “Recipient”), and Marinus Pharmaceuticals, Inc. |
|
| January 8, 2025 |
TABLE OF CONTENTS Exhibit (a)(1)(A) Offer to Purchase All Outstanding Shares of Common Stock of Marinus Pharmaceuticals, Inc. |
|
| January 7, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection wi |
|
| January 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 Marinus Pharmaceuticals, Inc. (Name of Subject Company — Issuer) Matador Subsidiary, Inc. a wholly owned subsidiary of Immedica Pharma AB (Names of Filing Persons — Offerors) Common Stock, par value $0.001 per share (Ti |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 23, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Co |
|
| December 30, 2024 |
TERMINATION AND RELEASE AGREEMENT Exhibit 10.1 EXECUTION VERSION TERMINATION AND RELEASE AGREEMENT THIS TERMINATION AND RELEASE AGREEMENT (“Agreement”) is made and entered into on this 23rd day of December, 2024 (the “Termination Effective Date”) by and between Orion Corporation ("Orion"), a corporation incorporated and existing under the laws of Finland, business identity code 1999212-6 (“Licensee”), having a principal place of b |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 29, 2024 MARINUS PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Co |
|
| December 30, 2024 |
Exhibit 99.1 EXECUTION VERSION TENDER AGREEMENT This TENDER AGREEMENT (“Agreement”), dated as of December 29, 2024, is made by and among Immedica Pharma AB, a corporation organized and existing under the laws of Sweden (“Parent”), Matador Subsidiary, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and the undersigned holder (“Stockholder”) of shares of c |
|
| December 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(d)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 Marinus Pharmaceuticals, Inc. (Name of Subject Company) Marinus Pharmaceuticals, Inc. (Name of Person(s) Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 568 |
|
| December 30, 2024 |
Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals, Inc. Exhibit 99.2 Press release Immedica to acquire biopharmaceutical company Marinus Pharmaceuticals, Inc. Stockholm, Sweden and Radnor, Pa. – December 30, 2024 - Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company committed to improving the lives of patients with seizure disorders, today announced that they h |
|
| December 30, 2024 |
Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: MARINUS PHARMACEUTICALS, INC., a Delaware corporation; IMMEDICA PHARMA AB, a corporation organized and existing under the laws of Sweden; and MATADOR SUBSIDIARY, INC., a Delaware corporation Dated as of December 29, 2024 Table of Contents Section 1 THE OFFER 1.1 The Offer 2 1.2 Company Actions 5 Section 2 MERGER TRANSACTION 2.1 Merger of Purchaser in |
|
| December 23, 2024 |
MARINUS PHARMACEUTICALS, INC. Amended And Restated CHANGE IN CONTROL SEVERANCE PLAN Exhibit 10.1 MARINUS PHARMACEUTICALS, INC. Amended And Restated CHANGE IN CONTROL SEVERANCE PLAN The Company adopted the Marinus Pharmaceuticals, Inc. Change in Control Severance Plan, originally effective as of November 7, 2016, and amended and restated effective as of December , 2024 for the benefit of certain employees of the Company, on the terms and conditions hereinafter stated. All capitali |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 17, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Co |
|
| December 10, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 6, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Com |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Co |
|
| November 14, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / Sofinnova Investments, Inc. Passive Investment SC 13G 1 d1152918813-g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the a |
|
| November 14, 2024 |
SC 13G/A 1 p24-3031sc13ga.htm MARINUS PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of Thi |
|
| November 14, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SC 13G/A 1 eventidemarinus-sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Marinus Pharmaceuticals, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) September 30, 2024 (Date of Event which Require |
|
| November 14, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / Cormorant Asset Management, LP Passive Investment SC 13G/A 1 cormorant-mrns093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* MARINUS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 56854Q200 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| November 14, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment SC 13G/A 1 finalmarinus.htm DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 1 Name of Issuer: MARINUS PHARMACEUTICALS INC Title of Class of Securities: Common Stock CUSIP Number: 56854Q200 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-36576 |
|
| November 12, 2024 |
Exhibit 99.2 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation November 2024 ©2024 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 12, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Co |
|
| November 12, 2024 |
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results ● ZTALMY® (ganaxolone) Q3 2024 net product revenue of $8.5 million representing growth of 56% versus Q3 2023 ● Narrowing full year 2024 ZTALMY net product revenue guidance to $33 to $34 million ● Reported results from Phase 3 TrustTSC trial and commenced process to explore strategic alter |
|
| November 1, 2024 |
EX-99 2 d895238dex99.htm EX-99 Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the i |
|
| November 1, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / Panacea Innovation Ltd - SC 13G Passive Investment SC 13G 1 d895238dsc13g.htm SC 13G Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of S |
|
| October 24, 2024 |
Exhibit 99.1 Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives Trial did not meet the primary endpoint of percent change in 28-day TSC-associated seizure frequency (p=0.09); results showed numerically higher response rates for ganaxolone than placebo Ganaxolone was g |
|
| October 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Com |
|
| October 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 2, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Comm |
|
| September 20, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (C |
|
| September 20, 2024 |
Exhibit 99.1 Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day Enrollment complete and on track to report topline data from the TrustTSC trial in tuberous sclerosis complex (TSC) in the first half of Q4 with NDA filing targeted for April 2025 TrustTSC maintained a double-blind discontinuation rate of 6.2% with 9 |
|
| August 13, 2024 |
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results ● ZTALMY® (ganaxolone) Q2 2024 net product revenue of $8.0 million representing strong growth of 87% versus Q2 2023 ● On track to achieve full year 2024 ZTALMY net product revenue guidance of between $33 and $35 million ● Completed enrollment in the Phase 3 TrustTSC trial of oral ganaxol |
|
| August 13, 2024 |
Exhibit 99.2 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation August 2024 ©2024 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current b |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-36576 MARI |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 13, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Comm |
|
| June 17, 2024 |
Exhibit 99.1 Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus RAISE trial met its first co-primary endpoint demonstrating rapid cessation of status epilepticus in a highly refractory patient population The trial failed to achieve statistical significance on the second co-primary endpoint of the proportion of patients not p |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commis |
|
| June 17, 2024 |
Exhibit 99.2 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation June 2024 ©2024 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward - looking statements reflecting the current b |
|
| June 6, 2024 |
Exhibit 10.2 FIRST AMENDMENT TO REVENUE INTEREST FINANCING AGREEMENT THIS FIRST AMENDMENT TO REVENUE INTEREST FINANCING AGREEMENT (this “Amendment”) is entered into as of June 6, 2024, by and between MARINUS PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and Sagard Healthcare Partners FUNDING Borrower SPE 1, lp, a Delaware limited partnership (as successor in interest by assignment |
|
| June 6, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Marinus Pharmaceuticals, Inc. |
|
| June 6, 2024 |
Exhibit 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT This SECOND AMENDMENT TO CREDIT AGREEMENT, dated as of June 6, 2024 (this “Amendment”), to that certain Credit Agreement dated as of May 11, 2021 (as amended by the Limited Consent and First Amendment to Credit Agreement, dated as of October 28, 2022, and as further amended, modified and restated from time to time prior to the date hereof, the “Exi |
|
| June 6, 2024 |
Exhibit 10.3 MARINUS PHARMACEUTICALS, INC. 2024 EQUITY INCENTIVE PLAN NONQUALIFIED STOCK OPTION AGREEMENT FOR NON-EMPLOYEE DIRECTORS Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.001 (the “Common Stock”), to the recipient (the “Grantee”) set forth on the Schedule to Nonqualified Sto |
|
| June 6, 2024 |
As filed with the Securities and Exchange Commission on June 6, 2024 As filed with the Securities and Exchange Commission on June 6, 2024 Registration No. |
|
| June 6, 2024 |
Exhibit 10.8 MARINUS PHARMACEUTICALS, INC. 2024 EQUITY INCENTIVE PLAN INCENTIVE STOCK OPTION AGREEMENT Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.001 (the “Common Stock”), to the recipient (the “Grantee”) set forth on the Schedule to Incentive Stock Option Agreement attached here |
|
| June 6, 2024 |
Exhibit 10.7 MARINUS PHARMACEUTICALS, INC. INDUCEMENT AWARD NONQUALIFIED STOCK OPTION AGREEMENT Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.001 (the “Common Stock”), to the recipient (the “Grantee”) set forth on the Schedule to Nonqualified Stock Option Agreement attached hereto ( |
|
| June 6, 2024 |
Exhibit 10.5 MARINUS PHARMACEUTICALS, INC. 2024 EQUITY INCENTIVE PLAN NONQUALIFIED STOCK OPTION AGREEMENT Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby grants an option (the “Option”) to purchase shares of its common stock, par value $0.001 (the “Common Stock”), to the recipient (the “Grantee”) set forth on the Schedule to Nonqualified Stock Option Agreement attache |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 6, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commiss |
|
| June 6, 2024 |
Exhibit 10.6 MARINUS PHARMACEUTICALS, INC. 2024 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby grants Restricted Stock Units (the “RSUs”) representing the right to receive shares of its common stock, par value $0.001 (the “Common Stock”), to the recipient (the “Grantee”) set forth on the Schedule to Restricted Sto |
|
| June 6, 2024 |
Exhibit 10.4 MARINUS PHARMACEUTICALS, INC. 2024 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT FOR NON-EMPLOYEE DIRECTORS Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby grants Restricted Stock Units (the “RSUs”) representing the right to receive shares of its common stock, par value $0.001 (the “Common Stock”), to the recipient (the “Grantee”) set forth on the |
|
| May 24, 2024 |
Exhibit 10.1 MARINUS PHARMACEUTICALS, INC. 2024 EQUITY INCENTIVE PLAN 1. PURPOSE The Plan is intended to (a) provide eligible persons with an incentive to contribute to the success of the Company and to operate and manage the Company’s business in a manner that will provide for the Company’s long-term growth and profitability to benefit its stockholders and other important stakeholders, including |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 22, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commiss |
|
| May 17, 2024 |
Exhibit 99.1 Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program Enrollment complete in Phase 3 TrustTSC trial with topline data anticipated in the first half of Q4 2024 USPTO grants additional method of use patent for ganaxolone in TSC RADNOR, Pa. – May 17, 2024 – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the deve |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commiss |
|
| May 8, 2024 |
Exhibit 99.2 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation May 2024 ©2024 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beli |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-36576 MAR |
|
| May 8, 2024 |
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results ● ZTALMY® (ganaxolone) Q1 2024 net product revenue of $7.5 million representing strong growth of 125% versus Q1 2023 ● Increased full year 2024 projected U.S. ZTALMY net product revenues to between $33 and $35 million ● Enrollment to be completed mid-May in the Phase 3 TrustTSC trial with |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commissi |
|
| April 25, 2024 |
EX-99.1 2 tm2412753d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Marinus Pharmaceuticals, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of |
|
| April 25, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares”) (Title of Class of Securities) 56854Q |
|
| April 19, 2024 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of Marinus Pharmaceuticals, Inc. and further agree to the filing of this agreement as an exhibi |
|
| April 19, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| April 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 15, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commi |
|
| April 15, 2024 |
Exhibit 99.1 Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results Trial did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024 Future development of IV ganaxolone in refractory status epilepticus to be |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 4, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commi |
|
| March 27, 2024 |
Exhibit 99.1 Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review RADNOR, Pa. – March 27, 2024 – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to developing and commercializing innovative therapeutics to treat seizure disorders, today affirmed its commitment to defending its patent portfo |
|
| March 5, 2024 |
Form of Amended and Restated Indemnification Agreement (Non-VC Directors). (Filed herewith.) EXHIBIT 10.7 AMENDED AND RESTATED INDEMNIFICATION AGREEMENT This Amended and Restated Indemnification Agreement (the “Agreement”) is entered into as of , by and among Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and the undersigned party (the “Indemnitee”). RECITALS A. The Company and (“Director”) previously entered into that certain Indemnification Agreement dated Septemb |
|
| March 5, 2024 |
Description of the Registrant’s Securities. (Filed herewith.) EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Marinus Pharmaceuticals, Inc. (“we,” “us” and “our”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), i |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 5, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commis |
|
| March 5, 2024 |
Subsidiaries of the Registrant. (Filed herewith.) Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Marinus Pharmaceuticals Emerald Limited, an Ireland company and wholly owned subsidiary. |
|
| March 5, 2024 |
Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results ● Phase 3 RAISE trial interim analysis enrollment target achieved with Data Monitoring Committee (DMC) review scheduled and topline results expected in first half of Q2 2024 ● Phase 3 TrustTSC trial approximately 85% enrolled with topline data now expected in first half of |
|
| March 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36576 Marinus Pha |
|
| March 5, 2024 |
Exhibit 99.2 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation March 2024 ©2024 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current be |
|
| March 5, 2024 |
Marinus Pharmaceuticals, Inc. Incentive Compensation Recovery Policy Exhibit 97 Marinus Pharmaceuticals, Inc. Incentive Compensation Recovery Policy Adopted by the Board of Directors (the “Board”) of Marinus Pharmaceuticals, Inc. (the “Company”) on October 11, 2023 The Company is committed to conducting business in accordance with the highest ethical and legal standards, and the Board believes that a culture that emphasizes integrity and accountability is in the be |
|
| February 14, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| February 14, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 56854Q200 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| February 14, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Marinus Pharmaceuticals, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriat |
|
| February 14, 2024 |
SC 13G/A 1 p24-0807sc13ga.htm MARINUS PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this |
|
| February 14, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / Lion Point Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4)1 Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 56854Q101 (CUSIP Number) Dece |
|
| February 13, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d1096314313g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 13, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / PRUDENTIAL FINANCIAL INC Passive Investment 13G HTML File DOCUMENT TYPE SC 13G TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 7, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule |
|
| February 6, 2024 |
MRNS / Marinus Pharmaceuticals, Inc. / FRANKLIN RESOURCES INC Passive Investment SC 13G 1 mari23in.htm CUSIP NO. 56854Q200 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MARINUS PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Fili |
|
| January 4, 2024 |
Exhibit 99.2 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation January 2024 ©2024 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current |
|
| January 4, 2024 |
Exhibit 99.1 Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update ● ZTALMY® (ganaxolone) Q4 2023 preliminary net product revenue of between $6.5 and $6.7 million; full year 2023 preliminary net product revenue of between $19.5 and $19.7 million ● Projected full year 2024 U.S. ZTALMY net product revenue of between $32 |
|
| January 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 4, 2024 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Comm |
|
| November 28, 2023 |
Exhibit 99.1 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation November 2023 ©2023 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current |
|
| November 28, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 28, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Co |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-36576 |
|
| November 7, 2023 |
Exhibit 99.2 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation November 2023 ©2023 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current |
|
| November 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Com |
|
| November 7, 2023 |
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2023 Financial Results ● ZTALMY® (ganaxolone) Q3 net product revenue of $5.4 million; 2023 net product revenue guidance increased to between $18.5 and $19 million ● Over 75% of patients required for the interim analysis are now enrolled in the Phase 3 RAISE trial in refractory status epilepticus; if the trial m |
|
| October 10, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of October 10, 2023, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the “Filers”). Each of the Filers may be required to file with |
|
| October 10, 2023 |
MRNS / Marinus Pharmaceuticals Inc / Cormorant Asset Management, LP Passive Investment SC 13G 1 schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 56854Q200 (CUSIP Number) September 29, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| September 28, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 28, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (C |
|
| September 28, 2023 |
Exhibit 99.1 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation September 2023 ©2023 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the curren |
|
| September 19, 2023 |
Exhibit 99.1 Marinus Pharmaceuticals Highlights Advancing Pipeline and Commercial Strategy at Investor and Analyst Event RAISE trial enrollment trends have returned to anticipated levels; on track for topline data in the first quarter of 2024, assuming pre-defined stopping criteria for interim analysis are met Continued execution of commercial launch of ZTALMY® (ganaxolone) with estimated net prod |
|
| September 19, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 19, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (C |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 21, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Comm |
|
| August 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 14, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Comm |
|
| August 10, 2023 |
Exhibit 99.2 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation August 2023 ©2023 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current b |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Comm |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-36576 MARI |
|
| August 10, 2023 |
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2023 Financial Results ● ZTALMY® (ganaxolone) second quarter net product revenue of $4.2 million; 2023 net product revenue guidance increased to between $17 and $18.5 million ● European Commission approved ZTALMY in CDKL5 deficiency disorder ● Interim analysis for the Phase 3 refractory status epilepticus tria |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commis |
|
| August 1, 2023 |
Exhibit 99.1 Marinus Pharmaceuticals Announces European Commission Approval of ZTALMY® (ganaxolone) for the Adjunctive Treatment of Epileptic Seizures Associated with CDKL5 Deficiency Disorder ZTALMY is the first treatment approved by the European Commission for seizures associated with CDKL5 deficiency disorder in children and adolescents RADNOR, Pa. – July 31, 2023 – Marinus Pharmaceuticals, Inc |
|
| July 6, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) June 26, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuan |
|
| June 29, 2023 |
As filed with the Securities and Exchange Commission on June 28, 2023 As filed with the Securities and Exchange Commission on June 28, 2023 Registration No. |
|
| June 29, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Marinus Pharmaceuticals, Inc. |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commiss |
|
| May 30, 2023 |
Exhibit 99.1 Marinus Pharmaceuticals Receives Positive CHMP Opinion for ZTALMY® (ganaxolone) for the Adjunctive Treatment of Seizures Associated With CDKL5 Deficiency Disorder The European Commission decision is expected within 67 days of the CHMP opinion RADNOR, Pa. – May 26, 2023 – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative t |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commiss |
|
| May 17, 2023 |
Exhibit 99.1 Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Sarah Noonberg, M.D., Ph.D. RADNOR, Pa. – May 17, 2023 – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Sarah Noonberg, M.D., Ph.D., to its Board of Directors. “ |
|
| May 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commiss |
|
| May 11, 2023 |
Exhibit 99.2 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation May 2023 ©2023 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beli |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 11, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commiss |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-36576 MAR |
|
| May 11, 2023 |
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2023 Financial Results ● ZTALMY® (ganaxolone) first quarter U.S. net product revenue of $3.3 million ● Now planning to conduct an interim analysis for the Phase 3 refractory status epilepticus trial in the second half of 2023 ● CHMP opinion for ZTALMY in CDKL5 deficiency disorder expected by end of May; Europea |
|
| April 18, 2023 |
Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors Exhibit 99.1 Marinus Pharmaceuticals Appoints Marvin H. Johnson, Jr. to its Board of Directors RADNOR, Pa. – April 18, 2023 – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Marvin H. Johnson, Jr. to its Board of Directors. “With over 34 years of diverse com |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 17, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commi |
|
| April 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| April 11, 2023 |
MARINUS PHARMACEUTICALS, INC. 5 Radnor Corporate Center, Suite 500 100 Matsonford Rd Radnor, PA 19087 April 11, 2023 VIA EDGAR Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Tim Buchmiller Re: Marinus Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed March 31, 2023 File No. 333-271041 Requ |
|
| March 31, 2023 |
Filing Fee Table (filed herewith) EX-FILING FEES 8 tm2310985d2ex-filingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Marinus Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Un |
|
| March 31, 2023 |
As filed with the Securities and Exchange Commission on March 31, 2023 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 31, 2023 Registration Statement No. |
|
| March 31, 2023 |
Form of Subordinated Debt Indenture (filed herewith) Exhibit 4.4 INDENTURE DATED AS OF , 20 BETWEEN MARINUS PHARMACEUTICALS, INC. as Issuer, AND as Trustee Providing for Issuance of Subordinated Debt Securities in Series Table of Contents Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commi |
|
| March 31, 2023 |
Form of Senior Debt Indenture (filed herewith) Exhibit 4.2 INDENTURE DATED AS OF , 20 BETWEEN MARINUS PHARMACEUTICALS, INC. as Issuer, AND as Trustee Providing for Issuance of Senior Debt Securities in Series Table of Contents Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section 1.04 |
|
| March 31, 2023 |
Exhibit 10.1 AMENDMENT NO. 1 TO THE EQUITY DISTRIBUTION AGREEMENT March 31, 2023 JMP Securities LLC 600 Montgomery Street, Suite 1100 San Francisco, California 94111 Ladies and Gentlemen: This Amendment No. 1 to the Equity Distribution Agreement (this “Amendment”) is entered into as of the date first written above by Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and JMP Se |
|
| March 31, 2023 |
Exhibit 1.2 AMENDMENT NO. 1 TO THE EQUITY DISTRIBUTION AGREEMENT March 31, 2023 JMP Securities LLC 600 Montgomery Street, Suite 1100 San Francisco, California 94111 Ladies and Gentlemen: This Amendment No. 1 to the Equity Distribution Agreement (this “Amendment”) is entered into as of the date first written above by Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company” |
|
| March 23, 2023 |
Exhibit 99.1 Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone in the Treatment of Lennox-Gastaut Syndrome RADNOR, Pa. – March 22, 2023 – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted orph |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 22, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commi |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 10, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commi |
|
| March 9, 2023 |
Subsidiaries of the Registrant. (Filed herewith.) Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Marinus Pharmaceuticals Emerald Limited, an Ireland company and wholly owned subsidiary. |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36576 Marinus Pha |
|
| March 9, 2023 |
Exhibit 10.42 Final Execution Copy CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY “[***]”, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL Collaboration and Supply Agreement between Marinus Pharmaceuticals, Inc. and Tenacia Biotechnology (Shanghai) Co., Ltd. Collaboration and Supply Agreement Th |
|
| March 9, 2023 |
Form of Amended and Restated Indemnification Agreement (Non-VC Directors). (Filed herewith.) EXHIBIT 10.7 AMENDED AND RESTATED INDEMNIFICATION AGREEMENT This Amended and Restated Indemnification Agreement (the “Agreement”) is entered into as of , by and among Marinus Pharmaceuticals, Inc., a Delaware corporation (the “Company”) and the undersigned party (the “Indemnitee”). RECITALS A. The Company and (“Director”) previously entered into that certain Indemnification Agreement dated Septemb |
|
| March 9, 2023 |
Exhibit 10.5 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT is effective on November 9, 2020, between Marinus Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, and Christina Shafer (the “Employee”). Recital: The parties desire to enter into this Agreement so as to provide for the employment of the Employee by the Company and for certain other matters in connection with such employment, all |
|
| March 7, 2023 |
Exhibit 99.2 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation March 2023 ©2023 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current be |
|
| March 7, 2023 |
Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results ● ZTALMY® U.S. net product revenue of $2.3 million for the fourth quarter of 2022 and $2.9 million for the fiscal year ended December 31, 2022 ● Company expects ZTALMY U.S. net product revenues of between $15 million and $17 million for the fiscal year ending December 31, 2 |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 7, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commis |
|
| February 14, 2023 |
SC 13G/A 1 tm236584d11sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Sta |
|
| February 14, 2023 |
MRNS / Marinus Pharmaceuticals Inc / Lion Point Capital, LP Passive Investment SC 13G/A 1 marinussc13ga3-021423.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)1 Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Secu |
|
| February 14, 2023 |
MRNS / Marinus Pharmaceuticals Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment SC 13G 1 marinuspharma13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Marinus Pharmaceuticals, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of |
|
| February 14, 2023 |
SC 13G/A 1 marinus13ga2-123122.htm AMENDMENT NO. 2 TO THE SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Ti |
|
| February 14, 2023 |
SC 13G/A 1 pt7213ga.htm SCHEDULE 13G/A, AMENDMENT #1 240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* (Name of Issuer) Marinus Pharmaceuticals, Inc. (T |
|
| February 14, 2023 |
SC 13G/A 1 p23-0577sc13ga.htm MARINUS PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This |
|
| February 13, 2023 |
MRNS / Marinus Pharmaceuticals Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d992844813g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Marinus Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 56854Q200 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 26, 2023 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Com |
|
| January 30, 2023 |
Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors Exhibit 99.1 Marinus Pharmaceuticals Appoints Christine Silverstein to its Board of Directors RADNOR, Pa. – January 30, 2023 – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the appointment of Christine Silverstein to its Board of Directors and Audit Committee. “Ms. Silverste |
|
| January 5, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): January 5, 2023 ? Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-36576 20-0198082 (State or other jurisdiction o |
|
| January 5, 2023 |
Exhibit 99.1 ? Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2022 ZTALMY? Net Product Revenue and Provides Business Update ? RADNOR, Pa. ? January 5, 2023 ? Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and preliminary U.S. ZTALM |
|
| December 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 2, 2022 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Com |
|
| December 5, 2022 |
Exhibit 99.1 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder AES Investor Breakfast December 5, 2022 ?2022 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking statements reflecting the c |
|
| December 5, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 5, 2022 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Com |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 13, 2022 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Co |
|
| November 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): November 16, 2022 ? Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-36576 20-0198082 (State or other jurisdiction |
|
| November 17, 2022 |
Exhibit 99.1 ? ? Marinus Pharmaceuticals Announces Collaboration with Tenacia Biotechnology for Ganaxolone Development and Commercialization in China ? Collaboration leverages Tenacia?s CNS, R&D, and local market expertise to support expansion of ganaxolone?s development programs and potentially provide additional access to patients globally ? Marinus to receive an upfront fee of $10 million and e |
|
| November 14, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi |
|
| November 14, 2022 |
240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Marinus Pharmaceuticals, Inc. (Title of Class of Securities) Common Stock, par value $0 |
|
| November 10, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 7, 2022 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Com |
|
| November 10, 2022 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Warrant No. [?] Number of Shares: [?] (subject to adjustment) Original Issue Date: [?], 2022 Marinus Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [?] or its registered assigns (the ?Holder?), is e |
|
| November 10, 2022 |
EX-1.1 2 tm2230152d1ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 10,526,316 Shares and Pre-funded Warrants to Purchase 2,105,264 Shares Marinus Pharmaceuticals, Inc. UNDERWRITING AGREEMENT November 7, 2022 SVB Securities LLC RBC Capital Markets, LLC Cantor Fitzgerald & Co. As Representatives of the Several Underwriters SVB Securities LLC 53 State Street, 40th Floor Boston, Massachusetts 02109 RBC Capital Mar |
|
| November 10, 2022 |
Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering Exhibit 99.2 Marinus Pharmaceuticals Announces Pricing of $60 Million Public Offering RADNOR, PA, November 7, 2022 - Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the pricing of its underwritten public offering of 10,526,316 shares of its common stock at a public offering pr |
|
| November 10, 2022 |
Marinus Pharmaceuticals Announces Proposed Public Offering Exhibit 99.1 Marinus Pharmaceuticals Announces Proposed Public Offering RADNOR, PA, November 7, 2022 ? Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has commenced an underwritten public offering of its securities. All of the securities to be sold in the offering are |
|
| November 9, 2022 |
Exhibit 107 The prospectus supplement to which this exhibit is attached is a final prospectus for the related offering. The maximum aggregate offering price of that offering is $68,997,900.49. |
|
| November 9, 2022 |
10,526,316 Shares of Common Stock Pre-Funded Warrants to Purchase 2,105,264 Shares of Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration No. 333-239780 PROSPECTUS SUPPLEMENT (To Prospectus dated July 27, 2020) 10,526,316 Shares of Common Stock Pre-Funded Warrants to Purchase 2,105,264 Shares of Common Stock We are offering 10,526,316 shares of our common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 2,105,264 |
|
| November 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): November 7, 2022 ? Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-36576 20-0198082 (State or other jurisdiction |
|
| November 7, 2022 |
Exhibit 10.4 ? SECURITY AGREEMENT by and among MARINUS PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?) the Company?s Subsidiaries named in the signature pages hereto or having acceded hereto pursuant to Section 24 (each a ?Subsidiary Guarantor? and, together with the Company, each a ?Grantor? and, collectively, the ?Grantors?) SAGARD HEALTHCARE ROYALTY PARTNERS, LP, as the Investor ( |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-36576 |
|
| November 7, 2022 |
Exhibit 99.2 Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Third Quarter 2022 Corporate and Financial Update November 2022 ?2022 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking sta |
|
| November 7, 2022 |
Exhibit 10.3 ? Execution Version REVENUE INTEREST FINANCING AGREEMENT by and between MARINUS PHARMACEUTICALS, INC., as the Company, and SAGARD HEALTHCARE ROYALTY PARTNERS, LP, as the Investor Dated October 28, 2022 ? ? ? ? TABLE OF CONTENTS ? ? Page ? ? ? ARTICLE I DEFINED TERMS AND RULES OF CONSTRUCTION? 1 ? Section 1.1 Defined Terms? 1 ? Section 1.2 Rules of Construction? 43 ? Section 1.3 Accoun |
|
| November 7, 2022 |
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results Exhibit 99.1 ? Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2022 Financial Results ? ? Initiated U.S. ZTALMY? (ganaxolone) launch in late July with over 50 completed CDKL5 deficiency disorder prescription enrollment forms; approximately 40% of those patients were on reimbursed therapy by the end of the third quarter ? ZTALMY generated $0.56 million in net product reve |
|
| November 7, 2022 |
Exhibit 10.5 ? Execution version LIMITED CONSENT AND FIRST AMENDMENT TO CREDIT AGREEMENT This LIMITED CONSENT AND FIRST AMENDMENT TO CREDIT AGREEMENT, dated as of October 28, 2022 (this ?Amendment?), to that certain Credit Agreement dated as of May 11, 2021 (as amended, modified and restated from time to time prior to the date hereof, the ?Existing Credit Agreement? and, the Existing Credit Agreem |
|
| November 7, 2022 |
SUBJECT TO COMPLETION, DATED NOVEMBER 7, 2022 TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| October 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 28, 2022 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Com |
|
| October 31, 2022 |
Exhibit 99.1 Marinus Pharmaceuticals Announces $32.5 Million Revenue Interest Financing Agreement with Sagard Healthcare Partners $32.5 million upfront payment provides non-dilutive capital to further support commercialization of ZTALMY® (ganaxolone); projected to extend cash runway into 2024 RADNOR, Pa. – October 31, 2022 – Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company de |
|
| September 23, 2022 |
? Exhibit 99.1 ? ? Marinus Pharmaceuticals Announces Exercise of First Contract Option by the Biomedical Advanced Research and Development Authority (BARDA) ? RADNOR, Pa. ? September 22, 2022 ? Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced the Biomedical Advanced Research an |
|
| September 23, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): September 21, 2022 ? Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-36576 20-0198082 (State or other jurisdictio |
|
| September 23, 2022 |
Exhibit 10.1 ? MARINUS PHARMACEUTICALS INC 1564975 Attn: MATTHEW O'BRIEN MARINUS PHARMACEUTICALS, INC. 5 RADNOR CORP CTR STE 500 RADNOR PA 19087 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended. Offers must acknowledge receipt of this amendment |
|
| August 29, 2022 |
Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million Exhibit 99.1 Marinus Pharmaceuticals Announces Closing of Sale of Priority Review Voucher for $110 Million RADNOR, Pa. ? August 29, 2022 ? Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has closed on the sale of its Rare Pediatric Disease Priority Review Voucher for $ |
|
| August 29, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2022 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Comm |
|
| August 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): August 11, 2022 ? Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-36576 20-0198082 (State or other jurisdiction o |
|
| August 11, 2022 |
Exhibit 99.2 NASDAQ: MRNS @ MarinusPharma Nasdaq: MRNS @MarinusPharma Photo Credit: Kelly Crews Photography Ryan (center) Living with CDKL5 deficiency disorder Corporate Presentation August 2022 ?2022 Marinus Pharmaceuticals. All Rights Reserved I To the extent that statements contained in this presentation are not descriptions of historical facts regarding Marinus, they ar e forward - looking sta |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| August 11, 2022 |
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results ? ? ZTALMY? can now be prescribed by healthcare professionals in the U.S. ? Second generation ganaxolone formulation demonstrates encouraging results in Phase 1 study in healthy volunteers and supports further clinical development ? Marinus? Phase 2 refractory status epilepticus (RSE) tr |
|
| July 14, 2022 |
Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million Exhibit 99.1 ? Marinus Pharmaceuticals Sells Rare Pediatric Disease Priority Review Voucher for $110 Million ? RADNOR, Pa. ? July 14, 2022 ? Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has entered into a definitive agreement to sell its Rare Pediatric Disease Prior |
|
| July 14, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): July 13, 2022 ? Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-36576 20-0198082 (State or other jurisdiction of |
|
| July 14, 2022 |
Exhibit 10.1 ? CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY ?[***]?, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ? ? Execution Version ? ? ? ? ? ASSET PURCHASE AGREEMENT BY AND BETWEEN NOVO NORDISK INC. AND MARINUS PHARMACEUTICALS, INC. dated as of July 13, 2022 ? ? ? ? TABLE OF CONTENTS |
|
| June 28, 2022 |
As filed with the Securities and Exchange Commission on June 27, 2022 As filed with the Securities and Exchange Commission on June 27, 2022 Registration No. |
|
| June 28, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Marinus Pharmaceuticals, Inc. |
|
| June 8, 2022 |
Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): June 8, 2022 ? Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-36576 20-0198082 (State or other jurisdiction of i |
|
| June 8, 2022 |
? ? ? Exhibit 99.1 ? Marinus Pharmaceuticals Expands Enrollment Criteria to Support Recruitment in Phase 3 RAISE Trial in Refractory Status Epilepticus ? RADNOR, Pa. ? June 8, 2022 ? Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it has amended the protocol for its Phase |
|
| June 1, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): May 19, 2022 ? Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-36576 20-0198082 (State or other jurisdiction of i |
|
| May 26, 2022 |
? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): May 24, 2022 ? Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-36576 20-0198082 (State or other jurisdiction of i |
|
| May 26, 2022 |
Submission of Matters to a Vote of Security Holders ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 ? Date of Report (Date of earliest event reported): May 25, 2022 ? Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Delaware 001-36576 20-0198082 (State or other jurisdiction of i |
|
| May 25, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2022 ? Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? Delaware 001-36576 20-0198082 (State or other jurisdiction of incorpora |
|
| May 25, 2022 |
Exhibit 10.1 ? EXECUTION VERSION ? ? th Floor ? ? Oaktree Capital Management, L.P. 333 South Grand Ave., 28th Floor Los Angeles, CA 90071 ? CONFIDENTIAL May 23, 2022 ? Letter Agreement re: Amendments to the Tranche C Commitment Marinus Pharmaceuticals, Inc. 5 Radnor Corporate Center 100 Matsonford Rd, Suite 500 Radnor, PA 19087 Attn: Steven Pfanstiel, Chief Financial Officer ? Mr. Pfanstiel: ? Ref |
|
| May 12, 2022 |
Exhibit 3.8 STATE OF DELAWARE CERTIFICATE OF CHANGE OF REGISTERED AGENT AND/OR REGISTERED OFFICE ? The corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1. The name of the corporation is Marinus Pharmaceuticals, Inc. ? 2. The Registered Office of the corporation in the State of Delaware is changed to 3411 Silverside Road Tat |
|
| May 12, 2022 |
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results Exhibit 99.1 Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2022 Financial Results ? ZTALMY? (ganaxolone) U.S. commercial launch on track for July 2022 ? Phase 3 RAISE trial in refractory status epilepticus continues to advance with resumption of screening and recruitment; data readout expected second half 2023 ? Site activations advance in Phase 3 TrustTSC trial in tub |
|
| May 12, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 12, 2022 Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-36576 20-0198082 (State or other jurisdiction of incorporation) (Commiss |
|
| May 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| April 11, 2022 |
DEFA14A 1 tm22120822defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 11, 2022 |
Definitive Proxy Statement on Schedule 14A filed with the Commission on April 11, 2022 DEF 14A 1 tm2212082d1def14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 31, 2022 |
Exhibit 10.1 ? ? MARINUS PHARMACEUTICALS INC 1564975 Attn: MICHAEL MCNAMARA MARINUS PHARMACEUTICALS, INC. 100 MATSONFORD RD STE 304 RADNOR PA 190874558 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers is extended, is not extended. Offers must acknowledge receipt of this am |
|
| March 31, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 29, 2022 ? Marinus Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? Delaware 001-36576 20-0198082 (State or other jurisdiction of incorpo |
|
| March 31, 2022 |
Exhibit 99.1 ? Marinus Pharmaceuticals Bolsters Financial Position With Drawdown of $30 Million Under Oaktree Capital Credit Facility ? BARDA research contract extended through 2023 ? RADNOR, Pa. ? March 31, 2022 ? Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced it has receive |
|
| March 24, 2022 |
Subsidiaries of the Registrant. (Filed herewith.) Exhibit 21 SUBSIDIARIES OF THE REGISTRANT Marinus Pharmaceuticals Emerald Limited, an Ireland company and wholly owned subsidiary. |
|
| March 24, 2022 |
Exhibit 4.3 to our Annual Report on Form 10-K for the year ended December 31, 2021 EXHIBIT 4.3 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 As of the date of the Annual Report on Form 10-K of which this exhibit forms a part, the only class of securities of Marinus Pharmaceuticals, Inc. (?we,? ?us? and ?our?) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), i |
|
| March 24, 2022 |
Exhibit 10.36 ? MARINUS PHARMACEUTICALS, INC. INDUCEMENT AWARD RESTRICTED STOCK UNIT AGREEMENT Marinus Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), hereby grants restricted Stock Units (the ?RSUs?) representing the right to receive shares of its common stock, par value $0.001 (the ?Stock?), to the recipient (the ?Grantee?) set forth on the Schedule to Restricted Stock Unit Agreem |
|
| March 24, 2022 |
Form of Amended and Restated Indemnification Agreement (Non-VC Directors). (Filed herewith.) EXHIBIT 10.10 AMENDED AND RESTATED INDEMNIFICATION AGREEMENT This Amended and Restated Indemnification Agreement (the ?Agreement?) is entered into as of , by and among Marinus Pharmaceuticals, Inc., a Delaware corporation (the ?Company?) and the undersigned party (the ?Indemnitee?). RECITALS A. The Company and (?Director?) previously entered into that certain Indemnification Agreement dated Septem |
|
| March 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| March 24, 2022 |
Exhibit 10.34 ? MARINUS PHARMACEUTICALS, INC. 2014 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT Marinus Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), hereby grants restricted Stock Units (the ?RSUs?) representing the right to receive shares of its common stock, par value $0.001 (the ?Stock?), to the recipient (the ?Grantee?) set forth on the Schedule to Restricted Stock U |
|
| March 24, 2022 |
Exhibit 10.35 ? MARINUS PHARMACEUTICALS, INC. INDUCEMENT AWARD RESTRICTED STOCK UNIT AGREEMENT Marinus Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), hereby grants restricted Stock Units (the ?RSUs?) representing the right to receive shares of its common stock, par value $0.001 (the ?Stock?), to the recipient (the ?Grantee?) set forth on the Schedule to Restricted Stock Unit Agreem |
